Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2025 09:00 ET | Source: e-therapeutics plc

e-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASH

LONDON, May 07, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced it will...
February 10, 2025 09:16 ET | Source: Transparency Market Research

PCSK9 Inhibitor Market Growth Accelerates to USD 9.3 Billion by 2034, Driven by Innovative Cholesterol-Lowering Solutions | Latest Report by Transparency Market Research, Inc.

Wilmington, Delaware, United States, Transparency Market Research Inc.-, Feb. 10, 2025 (GLOBE NEWSWIRE) -- The PCSK9 Inhibitor Market (Markt für PCSK9-Inhibitoren) is poised for significant growth,...
February 05, 2025 08:00 ET | Source: e-therapeutics plc

e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025

LONDON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, announced today that it will...
January 10, 2025 09:00 ET | Source: ADARx Pharmaceuticals

ADARx Pharmaceuticals to Present at the J.P. Morgan 43ʳᵈ Annual Healthcare Conference

ADARx to present at the JP Morgan Healthcare Conference
December 02, 2024 10:08 ET | Source: Transparency Market Research

Oligonucleotides Market Outlook 2034: Projected to Reach US$ 13.1 Billion by 2034, Driven by Expanding Applications in Biotechnology and Precision Medicine | TMR

Wilmington, Delaware, Transparency Market Research Inc.:, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The global oligonucleotides market (mercado de oligonucleótidos) is poised for significant growth,...
October 31, 2024 09:00 ET | Source: e-therapeutics plc

e-therapeutics Announces Business Updates and Interim Results

LONDON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced business...
October 15, 2024 04:30 ET | Source: invIOs GmbH

invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology

Funding secures ongoing pipeline progress and achievement of preclinical and clinical milestones Oral small molecule INV501: collaboration with Dana-Farber Cancer Institute (DFCI) making good...
September 17, 2024 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
August 01, 2024 16:04 ET | Source: NurExone Biologic Inc

NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer

NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer
July 30, 2024 09:05 ET | Source: ADARx Pharmaceuticals

ADARx Pharmaceuticals Appoints Ajim Tamboli, CFA as Chief Financial Officer

ADARx Pharmaceuticals Appoints Ajim Tamboli, CFA as Chief Financial Officer

Next Page keyboard_arrow_right